AU2019214358B2 - Modified lipidated Relaxin B chain peptides and their therapeutic use - Google Patents

Modified lipidated Relaxin B chain peptides and their therapeutic use Download PDF

Info

Publication number
AU2019214358B2
AU2019214358B2 AU2019214358A AU2019214358A AU2019214358B2 AU 2019214358 B2 AU2019214358 B2 AU 2019214358B2 AU 2019214358 A AU2019214358 A AU 2019214358A AU 2019214358 A AU2019214358 A AU 2019214358A AU 2019214358 B2 AU2019214358 B2 AU 2019214358B2
Authority
AU
Australia
Prior art keywords
xaa
ttds
group
variant
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019214358A
Other languages
English (en)
Other versions
AU2019214358A1 (en
Inventor
Elisabetta Bianchi
Olivier Duclos
Stéphane ILLIANO
Raffaele Ingenito
Paola MAGOTTI
Sergio Mallart
Claire MINOLETTI-HOCHEPIED
Alessia Santoprete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2019214358A1 publication Critical patent/AU2019214358A1/en
Application granted granted Critical
Publication of AU2019214358B2 publication Critical patent/AU2019214358B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019214358A 2018-01-31 2019-01-30 Modified lipidated Relaxin B chain peptides and their therapeutic use Active AU2019214358B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
EP18305094.7 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (2)

Publication Number Publication Date
AU2019214358A1 AU2019214358A1 (en) 2020-08-20
AU2019214358B2 true AU2019214358B2 (en) 2023-05-25

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019214358A Active AU2019214358B2 (en) 2018-01-31 2019-01-30 Modified lipidated Relaxin B chain peptides and their therapeutic use

Country Status (29)

Country Link
US (3) US10961295B2 (enExample)
EP (1) EP3746467B1 (enExample)
JP (1) JP7295871B2 (enExample)
KR (1) KR102755938B1 (enExample)
CN (1) CN111770934B (enExample)
AR (1) AR114325A1 (enExample)
AU (1) AU2019214358B2 (enExample)
BR (1) BR112020014834A2 (enExample)
CA (1) CA3089657A1 (enExample)
CO (1) CO2020008308A2 (enExample)
DK (1) DK3746467T3 (enExample)
ES (1) ES3058633T3 (enExample)
FI (1) FI3746467T3 (enExample)
HR (1) HRP20260016T1 (enExample)
IL (2) IL316406A (enExample)
LT (1) LT3746467T (enExample)
MA (1) MA52994A (enExample)
MX (1) MX2020008096A (enExample)
MY (1) MY199821A (enExample)
NZ (1) NZ766762A (enExample)
PH (1) PH12020551118A1 (enExample)
PL (1) PL3746467T3 (enExample)
PT (1) PT3746467T (enExample)
RS (1) RS67606B1 (enExample)
SG (1) SG11202006903WA (enExample)
SI (1) SI3746467T1 (enExample)
TW (1) TWI763972B (enExample)
UY (1) UY38069A (enExample)
WO (1) WO2019149782A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157829A1 (en) * 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
JP2017513875A (ja) * 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157829A1 (en) * 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOSSAIN, M. A. et al, "A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1", Chemical Science, 2016, vol. 7, no. 6, pages 3805-3819 *
HOSSAIN, M. A. et al, "Synthetic relaxins", Current Opinion in Chemical Biology, 2014, vol. 22, pages 47-55 *
HOSSAIN, M. A. et al, "The Minimal Active Structure of Human Relaxin-2", Journal of Biological Chemistry, 2011, vol. 286, no. 43, pages 37555-37565 *

Also Published As

Publication number Publication date
PT3746467T (pt) 2026-01-13
JP7295871B2 (ja) 2023-06-21
PL3746467T3 (pl) 2026-04-13
EP3746467B1 (en) 2025-10-08
IL276170B1 (en) 2024-11-01
HRP20260016T1 (hr) 2026-02-27
US20210292387A1 (en) 2021-09-23
JP2021512099A (ja) 2021-05-13
LT3746467T (lt) 2026-01-26
CA3089657A1 (en) 2019-08-08
WO2019149782A1 (en) 2019-08-08
US20240218042A1 (en) 2024-07-04
MY199821A (en) 2023-11-23
CO2020008308A2 (es) 2020-10-30
KR102755938B1 (ko) 2025-01-20
MX2020008096A (es) 2020-09-24
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
CN111770934B (zh) 2024-10-18
MA52994A (fr) 2021-05-05
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01
UY38069A (es) 2019-08-30
SG11202006903WA (en) 2020-08-28
IL276170B2 (en) 2025-03-01
EP3746467A1 (en) 2020-12-09
SI3746467T1 (sl) 2026-02-27
IL316406A (en) 2024-12-01
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
PH12020551118A1 (en) 2021-07-05
ES3058633T3 (en) 2026-03-12
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
RU2020126210A (ru) 2022-02-28
IL276170A (en) 2020-09-30
US11725036B2 (en) 2023-08-15
DK3746467T3 (da) 2026-01-12

Similar Documents

Publication Publication Date Title
AU2019214358B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
US10988524B2 (en) Modified relaxin B chain peptides and their therapeutic use
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
EP4482578A1 (en) Crf2 receptor agonists and their use in therapy
CA3229783A1 (en) Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
EP4658674A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)